Aprea Therapeutics
APRE
23 hedge funds and large institutions have $2.39M invested in Aprea Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
5.03% less ownership
Funds ownership: 32.82% → 27.79% (-5%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
22% less capital invested
Capital invested by funds: $3.07M → $2.39M (-$685K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$20.2K |
| 2 |
Morgan Stanley
New York
|
+$4.08K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.43K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$275K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25.7K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$24.6K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$22.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.94K |
APRE Hedge Fund Activity: Q3 2025 in Review
23 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2025, worth a combined $2.39M — down 22% from $3.07M a quarter earlier.
Fund positioning in APRE was balanced in Q3 2025: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $20.2K. The largest seller was Sio Capital Management, cutting an estimated $275K.
- 23 institutional investors held Aprea Therapeutics (APRE) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $2.39M of Aprea Therapeutics stock for Q3 2025, down 22% quarter-over-quarter.
- 2 funds opened new Aprea Therapeutics positions in Q3 2025 and 2 closed out, a net change of 0 holders.
- The largest Aprea Therapeutics buyer in Q3 2025 was HRT Financial, an estimated $20.2K added.
- The largest Aprea Therapeutics seller in Q3 2025 was Sio Capital Management, an estimated $275K sold.
Based on aggregated 13F filings for Q3 2025.